Contact

Terms of Use

1. ACCEPTANCE OF TERMS OF USE

The following Terms of Use govern your use of the website located at www.ninesquaretx.com, which is owned and operated by Nine Square Therapeutics, Inc. (“Nine Square”, “we,” “us” or “our”), and the services offered through the website (together, the “Site”). By accessing, browsing or using the Site or any pages of the Site, you are indicating that you have read and acknowledge and agree to be bound by these Terms of Use including any additional terms and conditions applicable to certain areas of the Site and posted in those areas of the Site, which are incorporated herein by reference, and Nine Square’s Website Privacy Policy. If you do not agree to every provision of these Terms of Use and Nine Square’s Privacy Policy, please do not access, browse or use the Site.

These Terms of Use may be revised at any time for any reason, and we will post the revised version of the Terms of Use on the Site. You can determine when we last updated these Terms of Use by referring to the “Last Updated” legend at the bottom of these Terms of Use. By accessing, browsing or using the Site following the posting of changes to these Terms of Use, you accept such changes. You agree to use the Site for lawful purposes only in a manner consistent with any and all applicable rules, laws and regulations. Any use of the Site in a manner inconsistent with these Terms of Use is deemed unauthorized access and may subject the user to civil or criminal penalties. We strongly recommend that you periodically visit this page of the Site to review these Terms of Use.

2. MEDICAL INFORMATION

THE SITE MAY CONTAIN GENERAL INFORMATION RELATING TO CERTAIN MEDICAL CONDITIONS AND THEIR TREATMENT. SUCH INFORMATION IS FOR INFORMATIONAL PURPOSES ONLY. THE CONTENT OF THE SITE IS NOT INTENDED IN ANY WAY TO SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE AND SHOULD NOT BE RELIED ON FOR MEDICAL DIAGNOSIS OR TREATMENT. ALWAYS SEEK THE ADVICE OF YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH PROVIDER WITH ANY QUESTIONS YOU MAY HAVE REGARDING A MEDICAL CONDITION. NEVER DISREGARD MEDICAL ADVICE OR DELAY IN SEEKING IT BECAUSE OF SOMETHING YOU HAVE READ ON THE SITE. YOU SHOULD CONSULT WITH YOUR DOCTOR BEFORE USING ANY PRODUCT DISCUSSED ON THE SITE.

3. SITE CONTENT

The Site and all material on the Site or contained therein, all text, graphics, and other works on the Site, the Sites’ design and coding, all computer programs used and licensed in connection with the Site, the look and feel of the Site, and all data and reports generated by the Site (collectively, the “Site Content”) are owned by us or a third party. These materials are protected under copyright, trademark and other laws. You may not copy, download, transmit, modify, distribute, or republish the Site or any portion of the Site, including without limitation any of the Site Content, without the prior written consent of Nine Square. You may not sell, publicly display, create derivative works of, reverse engineer, assign, sub-license, transfer, or otherwise exploit the Site or any Site Content. Use of any Site Content is prohibited without the prior written permission of Nine Square. As long as you comply with these Terms of Use, Nine Square grants you a personal, non-exclusive, non-transferable, non-sublicenseable right to access and make personal, non-commercial use of the Site in compliance with these Terms of Use. You shall not, and shall not permit anyone else to, directly or indirectly: (i) remove or alter proprietary notices or labels on or in the Site or Site Content; (ii) engage in any activity that interferes with or disrupts the Site or Site Content; (iii) engage in any fraudulent activity or activity that facilitates fraud; or (iv) otherwise act in violation of these Terms of Use. All rights not expressly granted herein are reserved.

4. NINE SQUARE TRADEMARKS

The trademarks, trade names, logos and service marks (collectively “Trademarks”) displayed on the Site are registered and unregistered trademarks and service marks owned by Nine Square, or its subsidiaries or affiliates, or a third party. The absence of a name, trademark, or logo in this list does not constitute a waiver of any and all intellectual property rights that Nine Square has established in any of its goods, services, names or logos. These trademarks and all other trademarks, service marks, logos, and company names (each a “Mark”) used in connection with the Site are the property of Nine Square or third parties and shall remain the property of Nine Square and such third parties. Nothing contained in the Site shall be construed as granting, by implication or otherwise, any license or right to use any such Mark without the prior written permission of Nine Square or such third party that may own such Mark. Your misuse of any such Mark, or any other Site Content, is strictly prohibited.

5. REGISTRATION

Some areas of the Site may require registration. Each registration is for a single user only. In consideration of your use of the Site, you agree to provide accurate, current and complete information about yourself or your company as requested on the Site registration form and to maintain and promptly update the information (including, in particular, your e-mail address) you provide as necessary to keep the information true, accurate, current, and complete. By accepting these Terms of Use, you represent and warrant that you are 18 years of age or older and that, if you have accepted these Terms of Use on behalf of any business (such as a corporation, partnership, limited liability company, or other organization) or other entity, you represent and warrant that you have legal authority to do so.

Any changes to your registration information should be made on the Site. If you provide information that is untrue, inaccurate, not current, or incomplete, we may suspend or terminate your account and refuse any and all current or future use of the Site.

After you register on the Site, you may receive a password for your use of the Site. You are responsible for keeping your password confidential. You will be responsible for all uses and activity that occurs through your password or account. You will close the browser window for the Site at the end of each use, and you will immediately notify us of any unauthorized use of your password. We cannot and will not be liable for any loss or damage arising from your failure to comply with this Section 5.

6. LEGAL REQUIREMENTS

Where Nine Square has a good faith belief that such action is necessary to comply with a judicial proceeding, court order, warrant, administrative order, civil investigative demand, subpoena, or other valid process, Nine Square may disclose IP addresses, personal information, and any contents of the Site where it is legally compelled to do so. Please see Nine Square’s Website Privacy Policy for additional information relating to the privacy and security of information collected hereunder.

7. YOUR USE OF THE SITE

You are solely responsible and liable for all data, information and other materials (“User Content”) that you submit, upload, post, e-mail or otherwise transmit (“Transmit”) in connection with the Site. In addition, we have no control over, and shall have no liability for, any damages resulting from the use (including without limitation republication) or misuse by any third party of information made public through the Site. IF YOU CHOOSE TO SUBMIT TO US, OR OTHERWISE MAKE ANY PERSONAL INFORMATION OR OTHER INFORMATION PUBLICLY AVAILABLE, YOU DO SO AT YOUR OWN RISK AND NINE SQUARE SHALL HAVE NO RESPONSIBILITY OR LIABILITY THEREFOR. You agree that you will not, and will not permit anyone else to, directly or indirectly: (a) Transmit any User Content that is unlawful, harmful, threatening, abusive, hateful, obscene, harassing, tortious, defamatory, libelous, slanderous, pornographic, profane, vulgar, offensive, lewd, invasive of another’s privacy or racially, ethnically or otherwise objectionable; (b) use the Site to harm minors in any way or to stalk, threaten, or otherwise violate the rights of others, including without limitation others’ privacy rights or rights of publicity, or harvest or collect personal information, including e-mail addresses, about other users of the Site; (c) Transmit any User Content that: (i) you do not have the right to Transmit, under any law or contractual or fiduciary relationships, including, without limitation, any inside information or proprietary or confidential information; (ii) infringes any patent, copyright, trademark or other intellectual property right or misappropriates any trade secret or right of privacy of any third-party; (iii) constitutes unsolicited or unauthorized advertising or promotional materials, “spam,” “chain letters,” or pyramid schemes; or (iv) contains any software routine, code, instruction or virus that is designed to disable, delete, modify, damage or erase software, hardware or data; (d) forge headers or otherwise manipulate identifiers in order to disguise any User Content Transmitted through the Site; (e) interfere with the Site or servers or networks used in connection with the Site; (f) interfere with the ability of others to use the Site; (g) copy, download, transmit, modify, reproduce, sell, resell, sub-license, distribute, publish create derivative works of, reverse engineer, assign, transfer or exploit for any commercial purposes, any portion of the Site, the Site Content or any User Content contained therein; (h) conduct your business using the Site in a way that is unfair, unlawful, or constitutes a deceptive business practice; (i) use any robot, spider, or other automatic device to monitor or copy portions of the Site or the Site Content without Nine Square’s prior written permission; (j) include in any third party website any hypertext link to any page or location within the Site without Nine Square’s prior written permission; (k) mirror or display the Site or any portion thereof in frames without Nine Square’s prior written permission; or (l) impersonate any person or entity, including, but not limited to, other users of the Site, falsely state or otherwise misrepresent your affiliation with any person or entity, or express or imply that we endorse any statement you make.

You acknowledge and agree that Nine Square may disclose or use any User Content that you Transmit for purposes that include, but are not limited to: (a) enforcing these Terms of Use; (b) complying with any laws, regulations or rules of any federal, state or local government or agency; (c) responding to claims that any User Content violates the rights of third parties; or (d) protecting the rights or property of Nine Square, its customers or the public. With respect to User Content that you Transmit to the Site, you grant Nine Square a perpetual, worldwide, royalty-free, non-exclusive license to use, copy, excerpt, reproduce, display, publish, modify, distribute and create derivative works of such User Content in any form or media, and to allow others to do so, however, Nine Square will only share personally identifiable information that you provide in accordance with Nine Square’s Privacy Policy. As between the parties, we own all right, title, and interest in and to all intellectual property rights in all materials, products or services developed by us, or on behalf of us by third parties, based on or including as a component thereof any such information as described above, and all generalized knowledge, skill, know-how and expertise relating to such information.

Nine Square does not and cannot review all User Content posted to the Site, or created by users accessing the Site, and is not in any manner responsible for the content of any User Content. You acknowledge that by providing you with the ability to view and distribute user-generated content on the Site, Nine Square is merely acting as a passive conduit for such distribution and is not undertaking any obligation or liability relating to any User Content or activities on the Site. However, Nine Square reserves the right to block, remove, move or edit any of the submissions in its sole discretion.

8. LINKED SITES

Nine Square has not reviewed all of the websites linked to the Site and is not responsible for the content of any third-party pages or any other websites linked to the Site. Nothing in the Site, including, without limitation, any links to other websites, should be construed as an endorsement of any products, services or information of any other persons or companies by Nine Square. Your choice to link to any other website is at your own risk, and you agree to comply with all terms and conditions relating to such websites. Nine Square reserves the right not to link, or to remove the link, to a particular website at any time. Any links to third party websites are provided as a convenience to you and are neither owned nor operated by Nine Square. Nine Square has no control over these linked websites and makes no representations or warranties with respect to these linked websites. Your viewing and use of any third-party websites is at your sole discretion and risk.

9. SPECIAL ADMONITIONS FOR INTERNATIONAL USE

The Site is hosted in the United States of America and is intended for use by residents of the United States of America only. All matters relating to the Site are governed exclusively by the laws of the State of Delaware in the United States of America and not the jurisdiction in which you are located. If you are located outside of the United States of America and you contact us, please be advised that any information you provide to us will be transferred to the United States of America and that by submitting information, you explicitly authorize such transfer.

10. INDEMNIFICATION

You agree to defend, indemnify and hold harmless Nine Square, its subsidiaries and affiliates, business partners, contractors, clients and service providers, and their respective officers, employees, agents, and representatives from and against any claims, liabilities, costs or damages, including reasonable attorneys’ fees and paralegal fees through final appeals, made by any third party, relating to or arising from your use of the Site, any User Content that you Transmit to or through the Site, any violation of these Terms of Use by you, or any other act or omission by you, including your violation of any rights of another, arising from your use of the Site.

11. AVAILABILITY AND FEATURES

Availability and features of the Site are subject to change without notice.

12. TERMINATION

You acknowledge and agree that Nine Square may terminate your access to use of the Site for any reason, including, without limitation, your violation of these Terms of Use. You agree that Nine Square may terminate your access to and use of the Site without prior notice and without any liability to you or any third party. You acknowledge and agree that Nine Square may modify, limit, suspend, or discontinue the Site or any part of the Site at any time, without notice or liability to you. Nine Square may also, from time to time, establish general rules and policies regarding use of the Site. Nine Square will post such rules and policies on the Site, and you agree that your compliance with such rules and policies shall be a condition of your use or continued use of the Site. Nine Square shall have no liability or responsibility with respect to any lost Site Content, User Content, or other data, such as the deletion of or failure to store Site Content, User Content, or other data. All provisions of these Terms of Use that by their nature should survive termination of your right to access and use the Site shall survive (including, but not limited to, all limitations on liability, releases, indemnification obligations, disclaimers of warranties, and intellectual property protections and licenses). Nine Square reserves the right to, but has no obligation to, store or keep copies of any Site Content, User Content, or other information, unless otherwise required by law or court order.

13. DISCLAIMERS AND LIMITATION OF LIABILITY

NINE SQUARE IS PROVIDING THE SITE AND ALL FEATURES OF THE SITE CONTENT ON AN “AS-IS,” “AS-AVAILABLE” BASIS. YOU EXPRESSLY AGREE THAT YOUR USE OF THE SITE IS AT YOUR SOLE RISK. NINE SQUARE DISCLAIMS ALL REPRESENTATIONS OR WARRANTIES OF ANY KIND TO THE EXTENT THAT THEY MAY BE EXCLUDED BY LAW, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT AS TO THE OPERATION OF THE SITE. NINE SQUARE DOES NOT WARRANT THAT THE SITE WILL OPERATE IN AN UNINTERRUPTED, SECURE OR ERROR-FREE MANNER. NINE SQUARE ASSUMES NO RESPONSIBILITY FOR AND MAKES NO WARRANTY OR REPRESENTATION AS TO THE ACCURACY, COMPLETENESS, RELIABILITY, CURRENTNESS, USEFULNESS, OR DECENCY OF THE SITE. NINE SQUARE MAKES NO WARRANTY REGARDING THE QUALITY, SAFETY, OR LEGALITY OF THE SITE, AND NINE SQUARE DOES NOT WARRANT THAT YOUR USE OF THE SITE WILL MEET YOUR REQUIREMENTS OR EXPECTATIONS.

YOU ASSUME TOTAL RESPONSIBILITY AND RISK FOR YOUR USE OF THE SITE. ANY SITE CONTENT DOWNLOADED OR OTHERWISE OBTAINED THROUGH YOUR USE OF THE SITE IS AT YOUR OWN RISK, AND YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGE DONE TO YOUR COMPUTER OR LOSS OF DATA THAT RESULTS FROM SUCH ACTIVITY.

IN NO EVENT SHALL NINE SQUARE, OR ITS SUBSIDIARIES, AFFILIATES, OFFICERS, DIRECTORS, EMPLOYEES, OR AGENTS (“AFFILIATED ENTITIES”) BE LIABLE, WHETHER IN CONTRACT, TORT (INCLUDING WITHOUT LIMITATION NEGLIGENCE) OR OTHERWISE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES, INCLUDING, BUT NOT LIMITED TO, LOSS OF DATA OR OTHER INTANGIBLES, INCOME OR PROFIT, LOSS OF OR DAMAGE TO PROPERTY OR CLAIMS OF THIRD PARTIES, EVEN IF NINE SQUARE HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING OUT OF OR RESULTING FROM (1) THE USE OF OR INABILITY TO USE THE SITE OR THE USER CONTENT; (2) ANY TRANSACTION CONDUCTED THROUGH OR FACILITATED BY THE SITE; (3) ANY CLAIM ATTRIBUTABLE TO ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE SITE, ANY SERVICES AND/OR USER CONTENT; (4) UNAUTHORIZED ACCESS TO OR ALTERATION OF YOUR TRANSMISSIONS OR DATA; OR (5) ANY OTHER MATTER RELATING TO THE SITE, ANY SERVICES, OR THE USER CONTENT. YOU SPECIFICALLY AGREE THAT NINE SQUARE IS NOT RESPONSIBLE OR LIABLE TO YOU OR ANYONE ELSE FOR ANY INFRINGEMENT OR VIOLATION OF YOUR RIGHTS BY ANY OTHER PARTY, INCLUDING, BUT NOT LIMITED TO, INTELLECTUAL PROPERTY RIGHTS, RIGHTS OF PUBLICITY, OR RIGHTS OF PRIVACY. YOUR SOLE AND EXCLUSIVE REMEDY FOR DISSATISFACTION WITH THE SITE IS TO STOP USING THE SITE. THE MAXIMUM LIABILITY OF NINE SQUARE AND THE AFFILIATED ENTITIES FOR ALL DAMAGES, LOSSES AND CAUSES OF ACTION, WHETHER IN CONTRACT, TORT (INCLUDING WITHOUT LIMITATION NEGLIGENCE) OR OTHERWISE WILL BE THE TOTAL AMOUNT, IF ANY, PAID BY YOU TO NINE SQUARE TO ACCESS AND USE THE SITE. IF YOU LIVE IN A JURISDICTION WHOSE LAWS PREVENT YOU FROM TAKING FULL RESPONSIBILITY AND RISK FOR YOUR USE OF THE SITE IN ACCORDANCE WITH THESE TERMS OF USE, NINE SQUARE’S LIABILITY IS LIMITED TO THE GREATEST EXTENT ALLOWED BY THE LAW OF THAT JURISDICTION.

14. GOVERNING LAW AND JURISDICTION

Nine Square operates the Site from its offices in South San Francisco, California, U.S.A. These Terms of Use and the transactions they contemplate, including without limitation their interpretation, construction, performance and enforcement shall be governed by the laws of the State of Delaware, U.S.A. without reference to conflict or choice of law provisions, as applicable to contracts made and performed entirely within such State. The International Convention on the Sale of Goods, and other international treaties that are not mandatory with respect to contracts made and performed entirely in the United States, shall not apply. The exclusive forum for the resolution of any dispute relating to these Terms of Use shall be the state and federal courts in Delaware, U.S.A., and you agree to personal jurisdiction of such courts over you with regard to any dispute relating to these Terms of Use and agree to service of process on you by e-mail to the address you have submitted on the Site, if any, and by any other means permitted by law.

15. NOTICE

All notices, demands, or consents given by you under these Terms of Use will be in writing and will be deemed given when delivered to Nine Square at the following contact:

Nine Square Therapeutics, Inc.
285 East Grand Avenue
Suite 2200
South San Francisco, CA 94080

Any notices to you may be made via either e-mail or postal mail to the address in Nine Square’s records or via posting on the Site.

Please report any violations of these Terms of Use to Nine Square at the contact listed above.

16. MISCELLANEOUS

You may not assign, sublicense or otherwise transfer any of your rights under these Terms of Use. If any provision of these Terms of Use is found to be invalid by any court having competent jurisdiction, the invalidity of that provision shall not affect the validity of the remaining provisions of these Terms of Use, which shall remain in full force and effect. Headings in these Terms of Use are for convenience only and shall have no legal meaning or effect. No action arising under these Terms of Use may be brought at any time more than twelve (12) months after the facts occurred upon which the cause of action arose. These Terms of Use, and not the conduct between us or any trade practice, shall control the interpretation of these Terms of Use between the parties respecting the Site. Nine Square’s failure to enforce a particular provision of these Terms of Use does not mean that Nine Square waives the right to enforce it in the future; Nine Square shall waive such a right only in writing.

These Terms of Use and all other written agreements duly executed between you and Nine Square in connection with your use of the Site constitute the entire agreement between you and Nine Square with respect to the subject matter hereof and supersede any prior or contemporaneous proposals, discussions, communications, or oral agreements heretofore made.

Last Updated: August 31, 2022

About Us

OUR SCIENCE

LEGAL

© Nine Square Therapeutics 2024, All Rights Reserved.
Website by The Grace Communication Group

James B. Summers, Ph.D.
Pharmaceutical Research and Strategy Advisor
During more than 30 years with Abbott and AbbVie, Dr. Summers held various senior R&D leadership positions, including vice president of neuroscience research, where he led efforts located in Ludwigshafen, Germany, Lake County, IL and Cambridge, MA, focused on the discovery of new drugs for the treatment of Alzheimer’s and Parkinson’s diseases, pain and psychiatric disorders. Under his leadership, the teams advanced more than 20 compounds into clinical development. Currently Dr. Summers serves as a board member and advisor to several biotechnology companies. He is also a venture partner with the Dementia Discovery Fund. Dr. Summers earned a Bachelor of Science in Chemistry, summa cum laude, from Denison University and a Doctorate in Organic Chemistry from Harvard University.
Roberto Zoncu, Ph.D.
SAB Member

Roberto is a professor of Molecular Therapeutics in the Department of Molecular and Cell Biology at the University of California, Berkeley. Prior to UC Berkeley, Roberto was a postdoctoral fellow at MIT’s Whitehead Institute, where he worked in Dr. David Sabatini’s laboratory. Roberto combined biochemical and microscopy-based assays to understand how lysosomes govern the signaling activity of the master growth regulator, mTORC1 kinase, and how these organelles generally function as metabolic signaling centers. For his doctoral studies, Roberto joined Dr. Pietro De Camilli’s laboratory. He used advanced microscopy and chemical genetic techniques to interrogate how a class of phospholipids known as phosphoinositides control endocytic vesicle traffic and maturation.

Roberto holds a Ph.D. in Cell Biology at Yale University. He studied molecular biology at the University of Pisa in Italy.

Aimee Kao, M.D., Ph.D.
SAB Member

Aimee is the John Douglas French Foundation Endowed professor at the University of California San Francisco School of Medicine and associate professor of Neurology at the University’s Weill Institute for Neurosciences. Aimee’s laboratory studies the basic mechanisms underlying neurodegenerative disorders. She is an expert in the diagnosis and treatment of age-related cognitive conditions such as Alzheimer’s disease, Lewy body disease and frontotemporal lobar degeneration.An award-winning scientist, Aimee She maintains an active clinic at UCSF’s Memory and Aging Center. At UCSF, she teaches medical students and serves as a research mentor to UCSF undergraduates for both theSummer Research Training Program (SRTP)and San Francisco Building Infrastructure Leading to Diversity (SF BUILD) program. Aimee also co-chairs the Neuroscience graduate program’s Diversity, Equity and Inclusion Committee.

Aimee completed her internship at the Beth Israel Deaconess Medical Center, residency in neurology at University of California, San Francisco, where she was chief resident, and received fellowship training in behavioral neurology and molecular genetics. She holds an MD and Ph.D. from the University of Iowa Carver College of Medicine and BS fromBrown University. She joined the UCSF faculty in 2007.

Robert Edwards, M.D.
SAB Member

Robert is the Cahill professor of Neurology and Physiology at the Weill Institute for Neurosciences at the University of California San Francisco School of Medicine. His work focuses on the molecular and cellular basis of neurotransmitter release and its role in Parkinson’s disease. In his research, he and his colleagues have identified several proteins implicated in Parkinson’s disease. Robert joined University of California, San Francisco from the faculty at University of California, Los Angeles. Among Robert’s many awards is the Established Investigator Award of the National Alliance for Research on Schizophrenia and Affective Disorders. He serves on editorial boards of several journals and the scientific advisory board of the Parkinson’s Foundation. He is a member of the National Academy of Medicine and the National Academy of Sciences.

He studied as a postdoctoral fellow with William J. Rutter after completing residency in clinical neurology at UCSF. Robert completed his M.D. at Johns Hopkins University School of Medicine and BA at Yale College. 

Sami Barmada, M.D., Ph.D.
SAB Member

Sami is the Angela Dobson Welch and Lyndon Welch research professor and associate professor of Neurology at University of Michigan and director of the University’s Michigan Brain Bank. Sami’s research focuses on combining basic biology with translational research and technology development to investigate unanswered questions in neurodegenerative diseases. His lab uses innovative technologies and methods involving fluorescence microscopy, computer science and engineering, bioinformatics, genome engineering and molecular biology to investigate critical abnormalities in RNA and protein metabolism in ALS and FTD.

Sami received his Ph.D. in the Medical Scientist Training Program at Washington University in St. Louis, where he investigated prion diseases. He went on to train with some of the premier clinicians and scientists in neurodegenerative diseases, such as Bruce Miller and Cathy Lomen-Hoerth while at University of California, San Francisco for his neurology residency. Throughout residency and postdoctoral fellowship, Sami worked with Steve Finkbeiner at the Gladstone Institutes, where he established one of the first human neuronal models of familial ALS and FTD.

Sami serves on the executive advisory board of the Robert Packard Center for ALS Research and scientific advisory boards of the Live Like Lou Foundation and Synapticure, Inc. He takes an active role in their efforts to raise awareness of ALS.

John Hood, Ph.D.
Endeavor Biomedicines

John is a 20-year veteran of the life sciences community in California and has founded and led several successful biotechnology companies. He is currently founder, chief executive officer and executive chairman of Endeavor Biomedicines, which was funded in 2021 to develop novel therapeutics for oncology and idiopathic pulmonary fibrosis. John has founded and led several other successful biotechnology companies including the now Bristol-Myers-Squibb-owned Impact Biomedicines, of which he was Founder and CEO.

He began his career in 2001 as director of research at TargeGen, where he co-discovered fedratinib, a treatment option approved worldwide for myelofibrosis, and led a team identifying small molecule therapeutics for cancer and eye disease. John is an inventor on more than 100 patents and author of more than 50 scientific articles.

He received a Ph.D. in Medical Physiology and a B.S. in Biochemistry from Texas A&M University.

Michael Ehlers, M.D., Ph.D. Apple Tree Partners (ATP)
Mike is general partner and chief scientific officer at Apple Tree Partners (ATP), where he applies expertise gained through a successful career leading research and development at major biopharmaceutical companies. He co-founded ATP’s portfolio companies Intergalactic Therapeutics (Cambridge, MA), Aulos Bioscience (Cambridge, MA), Ascidian Therapeutics (Boston, MA), and Replicate Bioscience (San Diego, CA). Prior to ATP, Mike was executive vice president of Research and Development at Biogen, where he led discovery sciences, translational medicine, clinical development, and regulatory sciences with a focus on neurological, immunological, and rare diseases. He expanded and diversified Biogen’s clinical portfolio, transformed its R&D productivity, advanced more than 20 novel clinical candidates, and oversaw global filings and approvals of Spinraza™ (nusinersen), the first drug approved for spinal muscular atrophy. Prior to Biogen, Mike was senior vice president at Biotherapeutics and chief scientific officer of Neuroscience at Pfizer. While there, he created and advanced the neuroscience and rare disease portfolios,directed global development activities in biologics design, synthesis, and manufacturing, steered academic collaborations focused on immunology and oncology,and brought 22 compounds into the clinic.  Before entering industry, Mike was a professor and investigator at the Howard Hughes Medical Institute at Duke University Medical Center. Hee pioneered studies on neuronal organelles and the trafficking of neurotransmitter receptors. He has received numerous awards, authored more than 100 scientific papers, and served on multiple editorial and advisory boards for the National Institutes of Health, private foundations and many other organizations across industry, academia and government.h Mike holds an M.D. and Ph.D. from Johns Hopkins University School of Medicine and  a B.S. in Chemistry from California Institute of Technology.
Lani Wu, Ph.D., and Steve Altschuler, Ph.D. (Observers)
Nine Square Therapeutics
University of California, San Francisco

Lani and Steve are co-founders of Nine Square Therapeutics and professors in the Department of Pharmaceutical Chemistry at the University of California, San Francisco . They together tackle systems-level questions in biology, disease and pharmacology in their laboratories at UCSF, where they developed a research program that combines experimental biology, data sciences and modeling to attack fundamental problems in cell biology and drug discovery. They entered systems biology and pharmacology through Rosetta Inpharmatics, a biotech startup. Their research careers started in mathematics at the interface of analysis and geometry, in which they found diverse applications, including the Poincaré Conjecture, robotics and computer graphics. They transitioned to engineering at Microsoft, co-leading an invention team that developed machine learning approaches to improve human-computer interactions in areas including computer vision, social networking and noisy speech recognition.  

Lani and Steve are pioneering members of the Bauer Fellows Program at Harvard University and the Green Center for Systems Biology at University of Texas Southwestern Medical Center, and visiting faculty at Mathematical Scientists Research Institutes in Berkeley and Google Brain in Mountain View.

Matthew P. Jacobson, Ph.D.
Nine Square Therapeutics
Apple Tree Partners (ATP)
University of California, San Francisco

Matthew P. Jacobson is a co-founder of Nine Square Therapeutics, a venture partner at Apple Tree Partners (ATP), and a biotech entrepreneur who has co-founded several other successful companies including Global Blood Therapeutics, Circle Pharma, and Relay Therapeutics. A Professor Emeritus in the Department of Pharmaceutical Chemistry at University of California San Francisco, he is a leading authority in computer-aided drug design and computational structural biology and biophysics. His research interests include docking against homology models and flexible protein binding sites, membrane permeability, antibody modeling, mechanisms of protein regulation by post-translational modifications, allostery, and pH. He is author of more than 200 research publications, the recipient of an NSF CAREER award and an Alfred P. Sloan Fellowship, and holder of several patents. Software written by Matt and his collaborators is widely used in the pharmaceutical industry.

Matt earned a Ph.D. in physical chemistry from the Massachusetts Institute of Technology in 1999 and did his postdoctoral work at Oxford University and Columbia University.

Spiros Liras, Ph.D.
Nine Square Therapeutics
Apple Tree Partners (ATP)

Spiros is co-founder of Nine Square Therapeutics and venture partner at Apple Tree Partners (ATP). He brings to ATP his decades-long career leading scientific innovation and discovery at some of the world’s foremost pharmaceutical companies. At ATP, Spiros  co-founded its portfolio companies Nereid Therapeutics (Cambridge, MA) , Initial Therapeutics (San Francisco, CA), Evercrisp Biosciences (Berkeley, CA), Deep Apple Therapeutics (San Francisco, CA), and Apertor Pharmaceuticals (Alameda, CA).

Prior to ATP, Spiros established and led the External Portfolio Innovation unit within Research and Development at Biogen. Prior to Biogen, he was vice president of Medicinal Chemistry at Pfizer, where he led teams to deliver clinical pipelines in disease areas including cardiovascular, metabolic and neuroscience. Under his leadership, his divisions explored cutting edge drug discovery concepts including selective protein translation inhibition, design of macrocycles for drug discovery in tough target space, allosterism, and tissue targeting design strategies for the delivery of small molecule, oligonucleotide therapeutics and other modalities.

Spiros earned a Ph.D. in Organic Chemistry from Iowa State University and completed postdoctoral studies at the University of Texas at Austin. Spiros is an adjunct professor in the Department of Pharmaceutical Chemistry at the University of California, San Francisco.

Parkin

Parkin is an intracellular protein that regulates mitochondrial quality control by selectively promoting the degradation of dysfunctional mitochondria, and Parkin mutations are implicated in early-onset Parkinson’s disease (PD). Nine has small molecule candidates that promote Parkin activity in lead optimization for PD, and plans to nominate a clinical candidate by [date].

TRPML1

TRPML1 is a lysosomal membrane protein that promotes autophagy by releasing calcium ions from the lysosome, and defects in the TRPML1 pathway have been linked to autophagic disorders and amyotrophic lateral sclerosis (ALS). Nine Square is evaluating small molecule candidates that activate TRPML1 to treat ALS, and plans to nominate a clinical candidate by the end of 2023.
Seth Harrison, M.D.
Apple Tree Partners (ATP)

Seth Harrison is a founder and managing partner of Apple Tree Partners (ATP), where he oversees $2.65 billion in committed venture capital. Since starting the firm in 1999, Seth has launched or invested in more than 30 companies focused on delivering cutting-edge therapies for unmet medical needs, with 19 now public or acquired. Prior to ATP Seth was a venture partner at Sevin Rosen Funds and a general partner at Oak Investment Partners.

Seth received an M.D. and MBA from Columbia University, completing a surgery internship at the Presbyterian Hospital in the City of New York. He earned an A.B. from Princeton University. He served on the board of the International Partnership for Microbicides from 2002-2010.

Robert holds an M.D. and Ph.D. from Ludwig-Maximilians Universität München in Germany and is a board-certified neurologist.

Robert Paul, M.D., Ph.D.
Chief Executive Officer

Robert has more than 20 years of experience in business and clinical development for neurodegenerative diseases. He joined Nine Square Therapeutics as CEO in January 2022 after serving as the chief medical officer of Alector, a leading immuno-neurology and immuno-oncology company. Robert joined Alector from Genentech, where he held leadership roles in the company’s Medical and Neuroscience Clinical Development organizations from 2009 to 2016. Prior to joining Genentech, Robert was a neurologist at the University of Munich and a consultant at Boston Consulting Group.

Robert holds an M.D. and Ph.D. from Ludwig-Maximilians Universität München in Germany and is a board-certified neurologist.